Quản Lý Tình Trạng Tâm Trạng Của Bản Thân: Sử Dụng Các Thuốc Ổn Định Tâm Trạng và Thuốc Chống Tâm Thần Trong Thai Kỳ

Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84(5):478–85. Robinson G. Controversies about the use of antidepressants in pregnancy. J Nerv Ment Dis. 2015;203:159–63. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179–84. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817–24. Vigod SN, Kurdyak PA, Demia CL, Gruneir A, et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based newborn study. BJOG. 2014;121(5):566–74. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146–50. van der Lugt NM, van de Maat JS, van Kamp IL, et al. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88(6):375–8. NICE. Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance. NICE clinical guideline. Updated 2014. Available at www.nice.org.uk/CG192 Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1–10. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. NEAD Study Group. Effects of fetal antiepileptic drug exposure: Outcomes at age 4.5 years. Neurology. 2012;78(16):1207–14. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. NEJM. 1991;324:674–7. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96:643–7. Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70(22 Pt 2):2152–8. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22. Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70. Alsaad AM, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis. Reprod Toxicol. 2015;53:45–50. Tennis P, Chan KA, Curkendall SM, et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res A Clin Mol Teratol. 2015;103(4):269–75. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–9. Cohen LS, Viguera AC, McInerney K, et al. The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Major Malformations. Presented at the Annual Meeting of the American Society of Clinical Psychopharmacology, June 2014 Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old Babies. PLoS One. 2014;9(5):e94788. Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298. Cohort study of antipsychotic use in pregnancy which did not demonstrate an increased risk of maternal obstetrical outcomes. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–35. Meta-analysis reviewing typical and atypical antipsychotics; no demonstrated difference in the risks of major malformations between these two groups; antipsychotic exposure was not associated with other poor obstetrical outcomes. Boden R et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: Population based cohort study. BMJ. 2012;345:e7085.